Bio-Gene Technology Ltd Ordinary Shares BGT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.08
- Day Range
- A$0.08–0.08
- 52-Week Range
- A$0.04–0.13
- Bid/Ask
- A$0.07 / A$0.08
- Market Cap
- A$15.10 Mil
- Volume/Avg
- 1,309 / 124,687
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bio-Gene Technology Ltd is an Australian biotechnology company engaged in the development and commercialization of insecticide products. It develops a patent-protected product platform based on a naturally occurring class of chemicals known as beta-triketones. Its product includes Qcide and Flavocid. Its target applications include agriculture, public health, and consumer and animal health. The firm operates in one business segment namely the conduct of research and development activities in the discovery of novel insecticides.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.bio-gene.com.au
Valuation
|
Metric
|
BGT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.09 |
Price/Sales | 20.60 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BGT
|
|---|---|
Quick Ratio | 6.61 |
Current Ratio | 7.08 |
Interest Coverage | — |
Quick Ratio
BGT
Profitability
|
Metric
|
BGT
|
|---|---|
Return on Assets (Normalized) | −58.50% |
Return on Equity (Normalized) | −69.70% |
Return on Invested Capital (Normalized) | −72.08% |
Return on Assets
BGT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dnkydkjbq | Fwyg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cnzhhgm | Fqhgmp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bhvsjyj | Whzrzl | $97.8 Bil | |
MRNA
| Moderna Inc | Lqlvjxg | Txhjn | $38.8 Bil | |
ARGX
| argenx SE ADR | Tzrzhvgqx | Hpym | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qcdbtnnyj | Wdwtg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fzfwhxwvj | Ckgxjx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fkylqrn | Fyydpt | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fqpwhkwwm | Hmkwxl | $12.5 Bil | |
INCY
| Incyte Corp | Gxdsjxy | Qjpbc | $11.5 Bil |